Aradigm Corp (ARDM) 0.2040 $ARDM
Smoking Cessation Therapeutics Pipeline Review 2014 - Detailing 16 Companies & 25 Drug Profiles
M2 - Fri May 02, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6rgwz8/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Smoking Cessation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Johnson & Johnson - Aradigm Corporation - GlaxoSmithKline plc - Pfizer Inc. - Arena Pharmaceuticals, Inc. - Targacept, Inc. - Invion Limited - Marinus Pharmaceuticals, Inc. - Royalty Pharma - Selecta Biosciences, Inc. - Embera NeuroTherapeutics, Inc. - NAL Pharmaceuticals Ltd. - BIOPROJET SCR - Astraea Therapeutics, LLC - Adial Pharmaceuticals, LLC - Istituto Italiano di Tecnologia Drug Profiles - GSK-598809 - lorcaserin hydrochloride - nadolol - ganaxolone - cycloserine - BP-1.4979 - meclizine hydrochloride - zonisamide - ARD-1600 - (oxazepam metyrapone) - ondansetron - SEL-068 - PF-05402536 - PF-06413367 - cycloserine - Small Molecule for Smoking Cessation - nicotine - NIC7-DT - CC-4 - Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation - Small Molecule for Smoking Cessation - Alpha 4 Beta 2 Neuronal Nicotinic Receptor Agonists for Smoking Cessation - Small Molecules to Inhibit FAAH for CNS Disorders - Nicotine Vaccine - NAL-2762 For more information visit http://www.researchandmarkets.com/research/6r..._cessation
Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
Business Wire - Wed Apr 30, 6:02AM CDT
Aradigm Corporation (OTCBB:ARDM.OB) ("Aradigm" or the "Company"
today announced the dosing of the first patient in the ORBIT-3 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin(R)) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE).
Results from Non-Tuberculous Mycobacteria (NTM) Study Using Aradigm's Liposomal Ciprofloxacin to be Presented at the American Thoracic Society 2014 International Conference
Business Wire - Tue Apr 15, 6:00AM CDT
Scientists from the Oregon State University, Corvallis (OSU) and Aradigm Corporation (OTCBB: ARDM) (the "Company" demonstrated that after 4 days of in vitro treatment of macrophages infected with Mycobacterium avium and Mycobacterium abscessus, Aradigm's liposomal ciprofloxacin was associated with a decrease of greater than 99% of these infections at ciprofloxacin concentrations of 200 mcg/ml, which approximate the peak sputum levels observed in humans in prior Aradigm clinical studies. At a lower concentration of 20mcg/ml, the liposomal concentrations still showed statistically significant decreases greater than 70% for M. avium and greater than 90% for M. abscessus. Unencapsulated ciprofloxacin showed smaller decreases which were only statistically significant at 200 mcg/ml. Liposomal ciprofloxacin at a concentration of 100 mcg/ml significantly reduced the population of these mycobacteria in a biofilm assay by more than 50% whereas unencapsulated ciprofloxacin did not show statistically significant decreases.
Aradigm Announces Fourth Quarter 2013 and Full Year Financial Results
Business Wire - Thu Mar 13, 6:00AM CDT
Aradigm Corporation (OTC BB: ARDM.OB) (the "Company" today announced financial results for the fourth quarter and full year ended December 31, 2013.
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2014 on February 11
Business Wire - Tue Feb 04, 6:00AM CST
Aradigm Corporation (OTCBB:ARDM) (the "Company" today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present at the 16th Annual BIO CEO & Investor Conference 2014 on Tuesday, February 11, 2014, at 10:30 a.m. ET. The event will be held at the Waldorf-Astoria Hotel in New York, New York.
Aradigm Corporation to participate at Biotech Showcase 2014
M2 - Thu Jan 09, 5:41AM CST
Specialist pharmaceutical company Aradigm Corporation (OTC Markets:ARDM) said on Wednesay that it will take part at Biotech Showcase 2014.
Aradigm to Present at Biotech Showcase 2014 on January 14
Business Wire - Wed Jan 08, 5:59AM CST
Aradigm Corporation (OTCBB:ARDM) (the "Company" today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present at Biotech Showcase 2014 on Tuesday, January 14, 2014, at 11: 30 a.m. Pacific time. The event will be held at Parc 55 Wyndham - Union Square Hotel, San Francisco, California.
Aradigm Corporation elects Dr. Juergen Froehlich as CMO
M2 - Wed Nov 20, 3:00AM CST
Pharmaceutical company Aradigm Corporation (OTC Markets:ARDM) announced on Tuesday that it has hired Dr Juergen Froehlich, MD as its chief medical officer.
Aradigm Announces Appointment of Dr. Juergen Froehlich as Chief Medical Officer
Business Wire - Tue Nov 19, 6:00AM CST
Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or the "Company" today announced that Juergen Froehlich, MD has been appointed as Aradigm's Chief Medical Officer. He joins Aradigm from Vertex Pharmaceuticals where he was Head of Regulatory Affairs, overseeing global submissions and approvals under accelerated review timelines of Kalydeco (ivacaftor) and the granting of two Breakthrough Designations for the orphan indication of cystic fibrosis.
Ohr Pharmaceutical (OHRP) Looks Good: Stock Jumps 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 12, 7:25AM CST
Ohr Pharmaceutical was a big mover last session, with shares rising over 7% on the day.
Aradigm Announces Changes to Its Board of Directors
Business Wire - Wed Sep 18, 6:00AM CDT
Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" or the "Company" today announced changes to its Board of Directors, including the retirement of Frank Barker and the appointment of Lafmin Morgan and David Bell.
Sigma-Tau PharmaSource Inc to supply Pulmaquin to Aradigm Corporation
M2 - Tue Sep 17, 9:20AM CDT
Sigma-Tau PharmaSource Inc revealed on Monday the launch of a broad manufacturing services agreement to provide clinical and commercial supplies of Pulmaquin to Aradigm Corporation (OTC BB:ARDM.OB).
Sigma-Tau PharmaSource, Inc. and Aradigm Corporation Sign Manufacturing Agreement for the Clinical and Commercial Supply of Pulmaquin
Business Wire - Mon Sep 16, 6:00AM CDT
Sigma-Tau PharmaSource, Inc. (a wholly owned subsidiary of Sigma-Tau Pharmaceuticals Inc.), a biopharmaceutical contract manufacturer specializing in complex injectable formulations, including liposomal drug delivery technology and PEGylation, and Aradigm Corporation (OTC BB: ARDM.OB), an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases, today announced that they have entered into a broad manufacturing services agreement whereby Sigma-Tau PharmaSource will provide Aradigm with clinical and commercial supplies of Pulmaquin(R). Pulmaquin is Aradigm's proprietary formulation of inhaled ciprofloxacin for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE).
Aradigm to Present at the Stifel Nicolaus 2013 Healthcare Conference
Business Wire - Mon Sep 09, 6:00AM CDT
Aradigm Corporation (OTCBB:ARDM) (the "Company" today announced that Nancy E. Pecota, Aradigm's Vice President, Finance and Chief Financial Officer, will present an overview of the Company at the Stifel Nicolaus 2013 Healthcare Conference at the Four Seasons Hotel in Boston on Thursday, September 12, 2013 at 10:20 am Eastern time.
Aradigm, Grifols Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 03, 2:15PM CDT
Aradigm Corporation announced the closing of an exclusive, worldwide license agreement with Grifols, S.A.
Smoking Cessation - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qr7jjs/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H2 2013" report to their offering. 'Smoking Cessation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Smoking Cessation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Smoking Cessation. Scope - A snapshot of the global therapeutic scenario for Smoking Cessation. - A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Smoking Cessation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Aradigm Corporation GlaxoSmithKline plc Laboratoires Pierre Fabre SA Pfizer Inc. Targacept, Inc. CBio Limited Marinus Pharmaceuticals, Inc. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Royalty Pharma Selecta Biosciences, Inc. Embera NeuroTherapeutics, Inc. Celtic Pharmaceutical Holdings L.P. NAL Pharmaceuticals Ltd. BIOPROJET SCR For more information visit http://www.researchandmarkets.com/research/qr..._cessation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Grifols and Aradigm Corporation Complete the Closing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin(R)
Business Wire - Wed Aug 28, 6:00AM CDT
Grifols, S.A. (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) ("Grifols" and Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" today announced the closing of the transaction that includes the exclusive, worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin(R)) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE). Aradigm has completed Phase 2b clinical trials in BE patients with Pulmaquin and Lipoquin.
Aradigm Corporation secures USD260,000 NIH grant to investigate new diagnoses tests of aspirations of gastrointestinal contents into respiratory tract
M2 - Mon Aug 12, 4:54AM CDT
Pharmaceutical company Aradigm Corporation (OTC BB:ARDM) revealed on Friday the receipt of a Small Business Initiative Research (SBIR) grant to investigate the development and validation of tests for gastro-esophageal reflux with aspirations into the respiratory tract.
OTC Daily Alert Stock Watch - Aradigm (OTCQB: ARDM )
WorldStockWire - Sat Aug 10, 8:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Aradigm Corporation reports Q2 net loss of USD2.7
M2 - Fri Aug 09, 6:36AM CDT
Pharmaceutical company Aradigm Corporation (OTC BB:ARDM.OB) announced on Thursday its net loss of USD2.7m (USD0.01 per share) for the second quarter ended 30 June 2013.
Smoking Cessation Therapeutics Pipeline Review 2014 - Detailing 16 Companies & 25 Drug Profiles
M2 - Fri May 02, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6rgwz8/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smoking Cessation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smoking Cessation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Smoking Cessation - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Smoking Cessation and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Smoking Cessation pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Johnson & Johnson - Aradigm Corporation - GlaxoSmithKline plc - Pfizer Inc. - Arena Pharmaceuticals, Inc. - Targacept, Inc. - Invion Limited - Marinus Pharmaceuticals, Inc. - Royalty Pharma - Selecta Biosciences, Inc. - Embera NeuroTherapeutics, Inc. - NAL Pharmaceuticals Ltd. - BIOPROJET SCR - Astraea Therapeutics, LLC - Adial Pharmaceuticals, LLC - Istituto Italiano di Tecnologia Drug Profiles - GSK-598809 - lorcaserin hydrochloride - nadolol - ganaxolone - cycloserine - BP-1.4979 - meclizine hydrochloride - zonisamide - ARD-1600 - (oxazepam metyrapone) - ondansetron - SEL-068 - PF-05402536 - PF-06413367 - cycloserine - Small Molecule for Smoking Cessation - nicotine - NIC7-DT - CC-4 - Small Molecules to Inhibit Nicotinic Acetylcholine Receptor for Smoking Cessation - Small Molecule for Smoking Cessation - Alpha 4 Beta 2 Neuronal Nicotinic Receptor Agonists for Smoking Cessation - Small Molecules to Inhibit FAAH for CNS Disorders - Nicotine Vaccine - NAL-2762 For more information visit http://www.researchandmarkets.com/research/6r..._cessation
Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
Business Wire - Wed Apr 30, 6:02AM CDT
Aradigm Corporation (OTCBB:ARDM.OB) ("Aradigm" or the "Company"
today announced the dosing of the first patient in the ORBIT-3 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin(R)) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE). Results from Non-Tuberculous Mycobacteria (NTM) Study Using Aradigm's Liposomal Ciprofloxacin to be Presented at the American Thoracic Society 2014 International Conference
Business Wire - Tue Apr 15, 6:00AM CDT
Scientists from the Oregon State University, Corvallis (OSU) and Aradigm Corporation (OTCBB: ARDM) (the "Company"
demonstrated that after 4 days of in vitro treatment of macrophages infected with Mycobacterium avium and Mycobacterium abscessus, Aradigm's liposomal ciprofloxacin was associated with a decrease of greater than 99% of these infections at ciprofloxacin concentrations of 200 mcg/ml, which approximate the peak sputum levels observed in humans in prior Aradigm clinical studies. At a lower concentration of 20mcg/ml, the liposomal concentrations still showed statistically significant decreases greater than 70% for M. avium and greater than 90% for M. abscessus. Unencapsulated ciprofloxacin showed smaller decreases which were only statistically significant at 200 mcg/ml. Liposomal ciprofloxacin at a concentration of 100 mcg/ml significantly reduced the population of these mycobacteria in a biofilm assay by more than 50% whereas unencapsulated ciprofloxacin did not show statistically significant decreases. Aradigm Announces Fourth Quarter 2013 and Full Year Financial Results
Business Wire - Thu Mar 13, 6:00AM CDT
Aradigm Corporation (OTC BB: ARDM.OB) (the "Company"
today announced financial results for the fourth quarter and full year ended December 31, 2013. Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2014 on February 11
Business Wire - Tue Feb 04, 6:00AM CST
Aradigm Corporation (OTCBB:ARDM) (the "Company"
today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present at the 16th Annual BIO CEO & Investor Conference 2014 on Tuesday, February 11, 2014, at 10:30 a.m. ET. The event will be held at the Waldorf-Astoria Hotel in New York, New York. Aradigm Corporation to participate at Biotech Showcase 2014
M2 - Thu Jan 09, 5:41AM CST
Specialist pharmaceutical company Aradigm Corporation (OTC Markets:ARDM) said on Wednesay that it will take part at Biotech Showcase 2014.
Aradigm to Present at Biotech Showcase 2014 on January 14
Business Wire - Wed Jan 08, 5:59AM CST
Aradigm Corporation (OTCBB:ARDM) (the "Company"
today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present at Biotech Showcase 2014 on Tuesday, January 14, 2014, at 11: 30 a.m. Pacific time. The event will be held at Parc 55 Wyndham - Union Square Hotel, San Francisco, California. Aradigm Corporation elects Dr. Juergen Froehlich as CMO
M2 - Wed Nov 20, 3:00AM CST
Pharmaceutical company Aradigm Corporation (OTC Markets:ARDM) announced on Tuesday that it has hired Dr Juergen Froehlich, MD as its chief medical officer.
Aradigm Announces Appointment of Dr. Juergen Froehlich as Chief Medical Officer
Business Wire - Tue Nov 19, 6:00AM CST
Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or the "Company"
today announced that Juergen Froehlich, MD has been appointed as Aradigm's Chief Medical Officer. He joins Aradigm from Vertex Pharmaceuticals where he was Head of Regulatory Affairs, overseeing global submissions and approvals under accelerated review timelines of Kalydeco (ivacaftor) and the granting of two Breakthrough Designations for the orphan indication of cystic fibrosis. Ohr Pharmaceutical (OHRP) Looks Good: Stock Jumps 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 12, 7:25AM CST
Ohr Pharmaceutical was a big mover last session, with shares rising over 7% on the day.
Aradigm Announces Changes to Its Board of Directors
Business Wire - Wed Sep 18, 6:00AM CDT
Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" or the "Company"
today announced changes to its Board of Directors, including the retirement of Frank Barker and the appointment of Lafmin Morgan and David Bell. Sigma-Tau PharmaSource Inc to supply Pulmaquin to Aradigm Corporation
M2 - Tue Sep 17, 9:20AM CDT
Sigma-Tau PharmaSource Inc revealed on Monday the launch of a broad manufacturing services agreement to provide clinical and commercial supplies of Pulmaquin to Aradigm Corporation (OTC BB:ARDM.OB).
Sigma-Tau PharmaSource, Inc. and Aradigm Corporation Sign Manufacturing Agreement for the Clinical and Commercial Supply of Pulmaquin
Business Wire - Mon Sep 16, 6:00AM CDT
Sigma-Tau PharmaSource, Inc. (a wholly owned subsidiary of Sigma-Tau Pharmaceuticals Inc.), a biopharmaceutical contract manufacturer specializing in complex injectable formulations, including liposomal drug delivery technology and PEGylation, and Aradigm Corporation (OTC BB: ARDM.OB), an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases, today announced that they have entered into a broad manufacturing services agreement whereby Sigma-Tau PharmaSource will provide Aradigm with clinical and commercial supplies of Pulmaquin(R). Pulmaquin is Aradigm's proprietary formulation of inhaled ciprofloxacin for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE).
Aradigm to Present at the Stifel Nicolaus 2013 Healthcare Conference
Business Wire - Mon Sep 09, 6:00AM CDT
Aradigm Corporation (OTCBB:ARDM) (the "Company"
today announced that Nancy E. Pecota, Aradigm's Vice President, Finance and Chief Financial Officer, will present an overview of the Company at the Stifel Nicolaus 2013 Healthcare Conference at the Four Seasons Hotel in Boston on Thursday, September 12, 2013 at 10:20 am Eastern time. Aradigm, Grifols Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 03, 2:15PM CDT
Aradigm Corporation announced the closing of an exclusive, worldwide license agreement with Grifols, S.A.
Smoking Cessation - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qr7jjs/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H2 2013" report to their offering. 'Smoking Cessation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Smoking Cessation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Smoking Cessation. Scope - A snapshot of the global therapeutic scenario for Smoking Cessation. - A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Smoking Cessation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Aradigm Corporation GlaxoSmithKline plc Laboratoires Pierre Fabre SA Pfizer Inc. Targacept, Inc. CBio Limited Marinus Pharmaceuticals, Inc. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Royalty Pharma Selecta Biosciences, Inc. Embera NeuroTherapeutics, Inc. Celtic Pharmaceutical Holdings L.P. NAL Pharmaceuticals Ltd. BIOPROJET SCR For more information visit http://www.researchandmarkets.com/research/qr..._cessation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Grifols and Aradigm Corporation Complete the Closing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin(R)
Business Wire - Wed Aug 28, 6:00AM CDT
Grifols, S.A. (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) ("Grifols"
and Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" today announced the closing of the transaction that includes the exclusive, worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin(R)) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE). Aradigm has completed Phase 2b clinical trials in BE patients with Pulmaquin and Lipoquin. Aradigm Corporation secures USD260,000 NIH grant to investigate new diagnoses tests of aspirations of gastrointestinal contents into respiratory tract
M2 - Mon Aug 12, 4:54AM CDT
Pharmaceutical company Aradigm Corporation (OTC BB:ARDM) revealed on Friday the receipt of a Small Business Initiative Research (SBIR) grant to investigate the development and validation of tests for gastro-esophageal reflux with aspirations into the respiratory tract.
OTC Daily Alert Stock Watch - Aradigm (OTCQB: ARDM )
WorldStockWire - Sat Aug 10, 8:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Aradigm Corporation reports Q2 net loss of USD2.7
M2 - Fri Aug 09, 6:36AM CDT
Pharmaceutical company Aradigm Corporation (OTC BB:ARDM.OB) announced on Thursday its net loss of USD2.7m (USD0.01 per share) for the second quarter ended 30 June 2013.
